Vérification…
Traduit automatiquement. Doses et mises en garde : vérifiez l'original en anglais. Lire en anglais
Accueil / Enregistré au Nigeria / Larinate 60 mg Injection

Larinate 60 mg Injection

NAFDAC REG NO: A4-3798 Médicament

Enregistré auprès de NAFDAC. Enregistrement actifAs of 30 October 2026 · synced automatically from official sources.
Produit
Larinate 60 mg Injection
Numéro NAFDAC
A4-3798
Principe actif
Artesunate
Dosage
60 mg
Forme
Powder for injection
Conditionnement
1 x 5 mL vial + 1 mL Sodium Bicarbonate ampoule + 5 mL Sodium Chloride ampoule
Fabricant
Non répertorié
Déposant / Titulaire :
IPCA Pharma Nigeria Limited
Approuvé
21 Dec 2020
Statut
Inactive Vue sur NAFDAC ↗
Enregistrement valable jusqu'au
20 Dec 2025
Alertes OMS
Non trouvé
Community reports
None
Times checked
0

About the medicine: Artesunate: uses, dosage and brands worldwide

What we found

  • Larinate 60 mg Injection is on the NAFDAC register with an active registration (A4-3798). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Larinate 60 mg Injection

Ce que dit la notice officielle. Si un médecin vous l'a prescrit, suivez l'ordonnance. La notice de votre boîte prime si elle est différente.

Pour qui

Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is indicated for the nutritional support of infants (including those of low birth weight) and young children requiring TPN via either central or peripheral infusion routes. Parenteral nutrition with Aminosyn-PF 7% is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young children where (1) the alimentary tract by the oral gastrostomy, or jejunostomy route, cannot or should not be used or adequate protein intake is not feasible by these routes, (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive …

Comment le prendre et à quelle fréquence
  • The total daily dose of the solution depends on the daily protein requirements and on the patient's metabolic and clinical response
  • Pediatric requirements for parenteral nutrition are constrained by the greater relative fluid requirements of the infant and greater caloric requirements per kilogram than in the adult
  • The recommended intravenous dose of Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is up to 2.5 g amino acid/kg/day for infants up to 10 kg
  • For infants and children larger than 10 kg, the total daily dose of amino acids should be up to 25 g amino acids/day for the first 10 kg of body weight plus 1 to 1.25 g amino acid for each kg of body weight over 10 kg
  • Initial amino acid dosage levels of 1 g/kg/day may be increased gradually in increments of 0.5 g/kg/day to approximate desired intake levels
  • Aminosyn-PF 7% should be diluted with dextrose prior to use
  • Nonprotein calories should constitute approximately 100 to 130 kcal/kg/day
  • Part of the nonprotein caloric requirement may be provided as lipid emulsion administered concurrently to provide up to 60% of daily calories at a dose not to exceed 4 g fat/kg/day
  • Fluid intake for the infant receiving central venous TPN should be approximately 125 mL/kg/day (range: 100 to 175 mL/kg/day), depending on the clinical condition of the patient
  • Premature
  • Infants with respiratory distress syndrome suspected of having a patent ductus arteriosus should be given fluids more cautiously. …
Talk to a doctor first if

Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is contraindicated in patients with untreated anuria, hepatic coma, inborn errors of amino acid metabolism (including those involving branched chain amino acid metabolism such as maple syrup urine disease and isovaleric acidemia), or hypersensitivity to one or more amino acids present in the solution.

Warnings

Safe, effective use of parenteral nutrition requires a knowledge of nutrition as well as clinical expertise in recognition and treatment of the complications which can occur. FREQUENT EVALUATION AND LABORATORY DETERMINATIONS ARE NECESSARY FOR PROPER MONITORING OF PARENTERAL NUTRITION. Studies should include blood sugar, serum proteins, kidney and liver function tests, electrolytes, hemogram, carbon dioxide content, serum osmolalities, blood cultures, and blood ammonia levels. Administration of amino acids in the presence of impaired renal function or gastrointestinal bleeding may augment an already elevated blood urea nitrogen. …

Effets secondaires possibles

Local reactions consisting of erythema, phlebitis and thrombosis at the infusion site have occurred with peripheral intravenous infusion of amino acids particularly if other substances, such as antibiotics, are also administered through the same site. In such cases the infusion site should be changed promptly to another vein. Use of large peripheral veins, inline filters, and slowing the rate of infusion may reduce the incidence of local venous irritation. Electrolyte additives should be spread throughout the day. Irritating additive medications may need to be injected at another venous site. …

Pregnancy and breastfeeding

Pregnancy Category C Animal reproduction studies have not been conducted with Aminosyn-PF 7%. It is also not known whether Aminosyn-PF 7% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Aminosyn-PF 7% should be given to a pregnant woman only if clearly needed.

If you take too much

In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS and PRECAUTIONS .

En cas d'oubli

Prenez-le dès que vous y pensez, sauf s'il est presque l'heure de la dose suivante. Dans ce cas, sautez la dose oubliée. Ne prenez jamais deux doses à la fois pour compenser. Vérifiez votre notice, certains médicaments font exception.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2025-10-17.

Label for Larinate 60 mg Injection, the active ingredient registered with NAFDAC.

Check your pack of Larinate 60 mg Injection

Add the expiry date on your pack for a full Trust Score.

Ou prenez la boîte en photo
Encore 3 vérifications gratuites aujourd'hui Sources officielles : FDA américaine · EMA (UE) · NAFDAC · alertes OMS

About Larinate 60 mg Injection

What is in Larinate 60 mg Injection?

Larinate 60 mg Injection contains Artesunate (60 mg), as powder for injection, according to its NAFDAC registration record.

Is Larinate 60 mg Injection registered with NAFDAC?

Yes. Larinate 60 mg Injection is listed on the NAFDAC register under registration number A4-3798, and its registration is active as of 30 October 2026.

Has Larinate 60 mg Injection been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Larinate 60 mg Injection in our automatically synced alert list.

How can I check that my pack of Larinate 60 mg Injection is genuine?

Run a free authenticity scan with the NAFDAC number A4-3798, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Larinate 60 mg Injection?

Follow your prescription or the leaflet in your pack. The official label says: The total daily dose of the solution depends on the daily protein requirements and on the patient's metabolic and clinical response. Pediatric requirements for parenteral nutrition are constrained by the greater relative fluid requirements of the infant and greater caloric requirements per kilogram than in the adult. The recommended intravenous dose of Aminosyn-PF 7%, Sulfite-F…

What is Larinate 60 mg Injection used for?

Aminosyn-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is indicated for the nutritional support of infants (including those of low birth weight) and young children requiring TPN via either central or peripheral infusion routes. Parenteral nutrition with Aminosyn-PF 7% is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young child (Summarised from the official U.S. FDA label for Larinate 60 mg Injection. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Larinate 60 mg Injection? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.